EX-99.2 3 a2022q2exhibit992.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SECOND QUARTER
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S. $12,197  11,919  2.3 % 2.3 — 
Europe 6,085  5,668 7.3  20.7  (13.4)
Western Hemisphere excluding U.S. 1,536  1,367  12.4 14.9  (2.5)
Asia-Pacific, Africa 4,202  4,358  (3.6) 4.7  (8.3)
International 11,823  11,393  3.8  13.9  (10.1)
      
Worldwide$24,020  23,312  3.0 % 8.0  (5.0)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SIX MONTHS
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$23,611  23,030 2.5 %2.5 — 
Europe 12,109  11,082  9.3  20.1  (10.8)
Western Hemisphere excluding U.S. 3,018  2,791  8.1  9.9  (1.8)
Asia-Pacific, Africa 8,708  8,730  (0.2) 5.6  (5.8)
International 23,835  22,603  5.5  13.3  (7.8)
      
Worldwide$47,446  45,633  4.0 % 7.8  (3.8)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SECOND QUARTER
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$1,687 1,751 (3.6)%(3.6)— 
    International2,118 2,103 0.67.3 (6.7)
3,805    3,854 (1.3)2.3 (3.6)
Pharmaceutical (1)
    U.S.7,159 6,869 4.2 4.2— 
    International6,158 5,611 9.8 22.1(12.3)
13,317    12,480 6.7 12.3(5.6)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.7,114 6,818 4.3 4.3— 
     International5,659 5,498 2.9 13.9(11.0)
12,773 12,316 3.7 8.6(4.9)
MedTech (2)
    U.S.3,351    3,299 1.6 1.6 — 
    International3,547 3,679 (3.6)5.1 (8.7)
 6,898    6,978 (1.1)3.4 (4.5)
U.S.12,197 11,919 2.3 2.3 — 
International11,823 11,393 3.8 13.9 (10.1)
Worldwide24,020 23,312 3.0 8.0 (5.0)
   
U.S.12,152 11,868 2.4 2.4 — 
International11,324 11,280 0.4 9.8 (9.4)
Worldwide excluding COVID-19 Vaccine (3)
$23,476 23,148 1.4 %6.0 (4.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SIX MONTHS
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$3,244 3,362 (3.5)%(3.5)— 
    International4,147 4,133 0.35.7 (5.4)
7,391    7,495 (1.4)1.6 (3.0)
Pharmaceutical (1)
    U.S.13,791 13,315 3.6 3.6— 
    International12,395 11,266 10.0 19.4(9.4)
26,186    24,581 6.5 10.8(4.3)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.13,671 13,164 3.9 3.9— 
     International11,514 11,153 3.2 11.9(8.7)
25,185 24,317 3.6 7.5(3.9)
MedTech (2)
    U.S.6,576    6,353 3.5 3.5 — 
    International7,293 7,204 1.2 8.0 (6.8)
 13,869    13,557 2.3 5.9 (3.6)
U.S.23,611 23,030 2.5 2.5 — 
International23,835 22,603 5.5 13.3 (7.8)
Worldwide47,446 45,633 4.0 7.8 (3.8)
   
U.S.23,491 22,879 2.7 2.7 — 
International22,954 22,490 2.1 9.5 (7.4)
Worldwide excluding COVID-19 Vaccine (3)
$46,445 45,369 2.4 %6.1 (3.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule



Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
SECOND QUARTER
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$24,020 100.0$23,312 100.03.0 
Cost of products sold7,919 33.07,587 32.54.4 
Gross Profit16,101 67.015,725 67.52.4 
Selling, marketing and administrative expenses6,226 25.96,073 26.12.5 
Research and development expense3,703 15.43,394 14.69.1 
Interest (income) expense, net(26)(0.1)28 0.1 
Other (income) expense, net273 1.1 (488)(2.1) 
Restructuring85 0.456 0.2 
Earnings before provision for taxes on income5,840 24.36,662 28.6(12.3)
Provision for taxes on income1,026 4.3384 1.7 167.2 
Net earnings$4,814 20.0$6,278 26.9(23.3)
Net earnings per share (Diluted)$1.80 $2.35 (23.4)
Average shares outstanding (Diluted)2,667.9 2,671.6 
Effective tax rate17.6 %5.8 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$8,171 34.0$7,776 33.45.1 
Net earnings$6,912 28.8$6,625 28.44.3 
Net earnings per share (Diluted)$2.59 $2.48 4.4 
Effective tax rate15.4 %14.8 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.




Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
SIX MONTHS
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$47,446 100.0$45,633 100.04.0 
Cost of products sold15,517 32.714,650 32.15.9 
Gross Profit31,929 67.330,983 67.93.1 
Selling, marketing and administrative expenses12,164 25.611,505 25.25.7 
Research and development expense7,165 15.16,572 14.49.0 
In-process research and development6101.3  
Interest (income) expense, net(38)(0.1)76 0.2 
Other (income) expense, net171 0.4 (1,370)(3.0) 
Restructuring155 0.3109 0.2 
Earnings before provision for taxes on income11,702 24.714,091 30.9(17.0)
Provision for taxes on income1,739 3.71,616 3.6 7.6 
Net earnings$9,963 21.0$12,475 27.3(20.1)
Net earnings per share (Diluted)$3.73 $4.67 (20.1)
Average shares outstanding (Diluted)2,669.2 2,674.0 
Effective tax rate14.9 %11.5 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$16,389 34.5$16,067 35.22.0 
Net earnings$14,041 29.6$13,549 29.73.6 
Net earnings per share (Diluted)$5.26 $5.07 3.7 
Effective tax rate14.3 %15.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Second Quarter
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$4,814$6,278
Pre-tax Adjustments
Intangible Asset Amortization expense1,095 1,202
Litigation related385(23)
Restructuring related128 108
Acquisition, integration and divestiture related - 14
(Gains)/losses on securities 109 (243)
Medical Device Regulation 1
70  56
COVID-19 Vaccine related costs 2
276  -
Consumer Health separation costs268-
Tax Adjustments
Tax impact on special item adjustments 3
(313)(135)
Consumer Health separation tax related costs2  -
Tax legislation and other tax related78  (632)
Adjusted Net Earnings, after tax$6,912$6,625
Average shares outstanding (Diluted)2,667.9 2671.6
Adjusted net earnings per share (Diluted)2.592.48
Operational adjusted net earnings per share (Diluted)2.75 
Notes:
1
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.
2
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.
3
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.





Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Six Months Ended
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$9,663$12,475
Pre-tax Adjustments
Intangible Asset Amortization expense2,203 2,417
Litigation related385(23)
IPR&D 610  -
Restructuring related200 212
Acquisition, integration and divestiture related ¹ - (524)
(Gains)/losses on securities520 (208)
Medical Device Regulation 2
130  102
COVID-19 Vaccine related costs 3
276  -
Consumer Health separation costs370-
Other(7)-
Tax Adjustments
Tax impact on special item adjustments 4
(706)(248)
Consumer Health separation tax related costs98  -
Tax legislation and other tax related(1) (654)
Adjusted Net Earnings, after tax$14,041$13,549
Average shares outstanding (Diluted)2,669.2 2674.0
Adjusted net earnings per share (Diluted)5.265.07
Operational adjusted net earnings per share (Diluted)5.50 
Notes:
1
Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.
3
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.
4
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 SECOND QUARTER 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical  MedTech  Total
 WW As Reported (1.3)%6.7 %(1.1)%3.0 %
 U.S. (3.6)%4.2 %1.6 %2.3 %
 International 0.6 %9.8 %(3.6)%3.8 %
 WW Currency (3.6)(5.6)(4.5)(5.0)
 U.S.
 International (6.7)(12.3)(8.7)(10.1)
 WW Operational 2.3 %12.3 %3.4 %8.0 %
 U.S. (3.6)%4.2 %1.6 %2.3 %
 International 7.3 %22.1 %5.1 %13.9 %
All Other Acquisitions and Divestitures0.60.10.00.1
 U.S. 0.20.2(0.2)0.1
 International 0.80.10.20.3
WW Adjusted Operational2.9 %12.4 %3.4 %8.1 %
 U.S. (3.4)%4.4 %1.4 %2.4 %
 International 8.1 %22.2 %5.3 %14.2 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
SIX MONTHS 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical MedTech Total
 WW As Reported (1.4)%6.5 %2.3 %4.0 %
 U.S. (3.5)%3.6 %3.5 %2.5 %
 International 0.3 %10.0 %1.2 %5.5 %
 WW Currency (3.0)(4.3)(3.6)(3.8)
 U.S.
 International (5.4)(9.4)(6.8)(7.8)
 WW Operational 1.6 %10.8 %5.9 %7.8 %
 U.S. (3.5)%3.6 %3.5 %2.5 %
 International 5.7 %19.4 %8.0 %13.3 %
Skin Health / Beauty
Dr. Ci Labo - Sedona0.50.1
U.S.0.00.0
International0.90.2
All Other Acquisitions and Divestitures0.10.10.10.1
 U.S. 0.20.1(0.1)0.1
 International 0.10.00.20.1
WW Adjusted Operational2.2 %10.9 %6.0 %8.0 %
 U.S. (3.3)%3.7 %3.4 %2.6 %
 International 6.7 %19.4 %8.2 %13.6 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$663675(1.8)%(1.8)%— %
Intl8187528.8 15.9 (7.1)
WW1,4821,4263.8 7.5 (3.7)
SKIN HEALTH / BEAUTY
US629659(4.5)(4.5)— 
Intl497511(2.8)5.1 (7.9)
WW1,126 1,170(3.7)(0.3)(3.4)
ORAL CARE
US1701653.4 3.4 — 
Intl224260(14.1)(8.7)(5.4)
WW394 426 (7.3)(4.0)(3.3)
BABY CARE
US8897(9.1)(9.1)— 
Intl287290(1.0)3.7 (4.7)
WW375 387 (3.1)0.5 (3.6)
WOMEN'S HEALTH
US338.9 8.9 — 
Intl2282270.1 7.2 (7.1)
WW2302300.2 7.2 (7.0)
WOUND CARE / OTHER
US133153(12.7)(12.7)— 
Intl65641.7 5.2 (3.5)
WW197216(8.4)(7.4)(1.0)
TOTAL CONSUMER HEALTH
US1,687 1,751 (3.6)(3.6) 
Intl2,118 2,103 0.6 7.3 (6.7)
WW$3,805 3,854 (1.3)%2.3 %(3.6)%
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,8532,7483.8 %3.8 %— %
Intl1,5591,4835.1 16.2 (11.1)
WW4,4114,2314.3 8.1 (3.8)
     REMICADE
     US391540(27.4)(27.4)— 
     US Exports (4)
4493(53.0)(53.0)— 
     Intl212255(17.2)(12.0)(5.2)
     WW647888(27.2)(25.6)(1.6)
     SIMPONI / SIMPONI ARIA
     US3012903.8 3.8 — 
     Intl266294(9.7)0.3 (10.0)
     WW566584(3.0)2.0 (5.0)
     STELARA
     US1,7311,49615.7 15.7 — 
     Intl86877811.6 24.0 (12.4)
     WW2,5992,27414.3 18.6 (4.3)
     TREMFYA
     US382 325 17.7 17.7 — 
     Intl214 155 38.3 54.6 (16.3)
     WW597 479 24.4 29.7 (5.3)
     OTHER IMMUNOLOGY
     US3 5 (50.1)(50.1)— 
     Intl0 1 **  *
     WW3 7 (59.2)(59.2)0.0
INFECTIOUS DISEASES
US415444(6.4)(6.4)— 
Intl90157556.879.3(22.5)
WW1,3161,01829.342.0(12.7)
     COVID-19 VACCINE
     US4551(11.5)(11.5)— 
     Intl499113**  *
     WW544164**  *
     EDURANT / rilpivirine
     US9 9 (1.7)(1.7)— 
     Intl215 253 (14.7)(5.4)(9.3)
     WW225 262 (14.3)(5.3)(9.0)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US355368(3.4)(3.4)— 
     Intl110137(20.2)(10.4)(9.8)
     WW464505(7.9)(5.3)(2.6)
     OTHER INFECTIOUS DISEASES
     US616(62.5)(62.5)— 
     Intl77717.410.9(3.5)
     WW8388(5.4)(2.6)(2.8)
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$8968426.5%6.5%—%
Intl837963(13.0)(4.8)(8.2)
WW1,7341,804(3.9)0.5(4.4)
     CONCERTA / methylphenidate
     US38359.49.4
     Intl123127(2.2)8.0(10.2)
     WW1611610.38.3(8.0)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US6916457.37.3
     Intl362380(4.6)6.3(10.9)
     WW1,0541,0242.96.9(4.0)
     RISPERDAL CONSTA
     US6572(8.9)(8.9)
     Intl6084(28.0)(19.0)(9.0)
     WW125155(19.3)(14.4)(4.9)
     OTHER NEUROSCIENCE
     US1029111.811.8
     Intl292373(21.8)(17.2)(4.6)
     WW393464(15.2)(11.6)(3.6)
ONCOLOGY
US1,6791,46214.914.9
Intl2,3622,07314.026.9(12.9)
WW4,0423,53514.321.9(7.6)
     DARZALEX
     US1,021 770 32.632.6
     Intl965 663 45.561.9(16.4)
     WW1,986 1,433 38.646.1(7.5)
     ERLEADA
     US233 193 20.620.6
     Intl218 109  *  *    *
     WW450 302 49.556.9(7.4)
     IMBRUVICA
     US349 454 (23.1)(23.1)
     Intl620 662 (6.3)3.6(9.9)
     WW970 1,116 (13.1)(7.2)(5.9)
     ZYTIGA / abiraterone acetate
     US1921 (12.2)(12.2)
     Intl486542(10.2)1.5(11.7)
     WW505563(10.3)0.9(11.2)
     OTHER ONCOLOGY
     US57 23 **
     Intl7297(25.7)(17.3)(8.4)
     WW1301207.514.4(6.9)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$560 595 (5.8)%(5.8)%— %
Intl284 275 2.8 15.3 (12.5)
WW843 870 (3.1)0.9 (4.0)
     OPSUMIT
     US265 290 (8.7)(8.7)— 
     Intl173 172 0.5 13.1 (12.6)
     WW438 463 (5.3)(0.6)(4.7)
     UPTRAVI
     US272 268 1.4 1.4 — 
     Intl56 45 26.2 38.3 (12.1)
     WW328 313 4.9 6.6 (1.7)
     OTHER PULMONARY HYPERTENSION
     US23 36 (36.2)(36.2)— 
     Intl55 59 (8.1)4.8 (12.9)
     WW78 95 (18.7)(10.7)(8.0)
CARDIOVASCULAR / METABOLISM / OTHER
US757780(3.0)(3.0)— 
Intl215241(10.9)(3.4)(7.5)
WW9721,021(4.8)(3.1)(1.7)
     XARELTO
     US609 569 7.1 7.1 — 
     Intl  — — — 
     WW609 569 7.1 7.1 — 
     INVOKANA / INVOKAMET
     US55 96 (42.9)(42.9)— 
     Intl65 64 2.4 10.2 (7.8)
     WW120 160 (24.9)(21.8)(3.1)
     OTHER
     US93 116 (19.5)(19.5)— 
     Intl150 178 (15.6)(8.3)(7.3)
     WW243 293 (17.2)(12.7)(4.5)
TOTAL PHARMACEUTICAL
US7,1596,8694.2 4.2  
Intl6,1585,6119.8 22.1 (12.3)
WW$13,31712,4806.7 %12.3 %(5.6)%
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5)
INTERVENTIONAL SOLUTIONS
US$525 475 10.5 %10.5 %— %
Intl525 572(8.1)1.0 (9.1)
WW1,049 1,0460.3 5.3 (5.0)
ORTHOPAEDICS
US1,338 1,323 1.1 1.1 — 
Intl820 904 (9.3)(0.6)(8.7)
WW2,157 2,227 (3.1)0.5 (3.6)
     HIPS
     US240 233 3.4 3.4 — 
     Intl148 159 (6.6)1.7 (8.3)
     WW388 391 (0.7)2.7 (3.4)
     KNEES
     US216 210 2.9 2.9 — 
     Intl133 140 (4.6)3.9 (8.5)
     WW349 350 (0.1)3.3 (3.4)
     TRAUMA
     US464 447 3.9 3.9 — 
     Intl232 263 (11.8)(1.7)(10.1)
     WW696 710 (1.9)1.8 (3.7)
     SPINE, SPORTS & OTHER
     US418 434 (3.7)(3.7)— 
     Intl306 343 (10.6)(2.5)(8.1)
     WW724 777 (6.8)(3.2)(3.6)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5) (Continued)
SURGERY
US$992 1,035 (4.1)(4.1)— %
Intl1,458 1,487 (2.0)5.9 (7.9)
WW2,450 2,522 (2.8)1.8 (4.6)
     ADVANCED
US454 459 (1.1)(1.1) 
Intl702 708 (0.9)6.6 (7.5)
WW1,156 1,168 (1.0)3.6 (4.6)
     GENERAL
US538 576 (6.4)(6.4) 
Intl756 779 (3.0)5.3 (8.3)
WW1,294 1,354 (4.5)0.3 (4.8)
VISION
US496 467 6.2 6.2  
Intl745 716 4.0 13.9 (9.9)
WW1,241 1,183 4.9 10.9 (6.0)
     CONTACT LENSES / OTHER
US374 352 6.6 6.6  
Intl519 517 0.4 11.0 (10.6)
WW894 868 2.9 9.2 (6.3)
     SURGICAL
US122 115 5.15.1— 
Intl225 199 13.621.5 (7.9)
WW347 314 10.515.5(5.0)
TOTAL MEDTECH
US3,351 3,299 1.6 1.6  
Intl3,547 3,679 (3.6)5.1 (8.7)
WW$6,898 6,978 (1.1)%3.4 %(4.5)%
See footnotes at end of schedule









Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$1,3331,2744.6 %4.6 %— %
Intl1,6091,42512.9 18.6 (5.7)
WW2,9432,6999.0 12.0 (3.0)
SKIN HEALTH / BEAUTY
US1,1731,293(9.2)(9.2)— 
Intl9651,040(7.2)(1.1)(6.1)
WW2,138 2,333(8.3)(5.6)(2.7)
ORAL CARE
US313328(4.6)(4.6)— 
Intl447514(13.0)(8.6)(4.4)
WW760 843 (9.7)(7.1)(2.6)
BABY CARE
US173193(10.3)(10.3)— 
Intl557583(4.4)(0.6)(3.8)
WW730 776 (5.9)(3.0)(2.9)
WOMEN'S HEALTH
US768.1 8.1 — 
Intl4524461.3 7.7 (6.4)
WW4584521.4 7.7 (6.3)
WOUND CARE / OTHER
US245268(8.6)(8.6)— 
Intl117125(6.6)(4.5)(2.1)
WW361393(8.0)(7.3)(0.7)
TOTAL CONSUMER HEALTH
US3,244 3,362 (3.5)(3.5) 
Intl4,147 4,133 0.3 5.7 (5.4)
WW$7,391 7,495 (1.4)%1.6 %(3.0)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$5,3545,1613.7 %3.7 %— %
Intl3,1762,9846.4 14.9 (8.5)
WW8,5308,1454.7 7.8 (3.1)
     REMICADE
     US7491,029(27.1)(27.1)— 
     US Exports (4)
124150(17.5)(17.5)— 
     Intl437487(10.3)(6.7)(3.6)
     WW1,3101,665(21.4)(20.3)(1.1)
     SIMPONI / SIMPONI ARIA
     US5885457.9 7.9 — 
     Intl549601(8.6)(0.8)(7.8)
     WW1,1371,146(0.8)3.3 (4.1)
     STELARA
     US3,1102,82710.0 10.0 — 
     Intl1,7771,59511.4 20.8 (9.4)
     WW4,8874,42210.5 13.9 (3.4)
     TREMFYA
     US773 599 29.1 29.1 — 
     Intl413 298 38.6 51.4 (12.8)
     WW1,187 897 32.3 36.6 (4.3)
     OTHER IMMUNOLOGY
     US9 12 (24.8)(24.8)— 
     Intl03 **  *
     WW9 15 (39.0)(39.0)0.0
INFECTIOUS DISEASES
US876956(8.3)(8.3)— 
Intl1,7371,06063.9 79.0 (15.1)
WW2,6132,01629.6 37.6 (8.0)
     COVID-19 VACCINE
     US120151(20.4)(20.4)— 
     Intl881113**  *
     WW1,001264**  *
     EDURANT / rilpivirine
     US18 19 (7.4)(7.4)— 
     Intl454 486 (6.5)2.2 (8.7)
     WW473 505 (6.5)1.9 (8.4)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US724748(3.2)(3.2)— 
     Intl242303(20.3)(13.4)(6.9)
     WW9651,051(8.1)(6.1)(2.0)
     OTHER INFECTIOUS DISEASES
     US1437(62.5)(62.5)— 
     Intl1601581.3 5.8 (4.5)
     WW174196(10.9)(7.2)(3.7)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$1,7391,6137.9 %7.9 %— %
Intl1,7351,906(8.9)(1.7)(7.2)
WW3,4753,519(1.2)2.7 (3.9)
     CONCERTA / methylphenidate
     US7382(11.3)(11.3)
     Intl245250(1.7)5.8(7.5)
     WW318332(4.1)1.5(5.6)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US1,3521,2349.6 9.6 
     Intl749756 (0.8)8.1 (8.9)
     WW2,1021,9895.7 9.0 (3.3)
     RISPERDAL CONSTA
     US128139(7.7)(7.7)
     Intl126173(27.1)(19.3)(7.8)
     WW254312(18.4)(14.1)(4.3)
     OTHER NEUROSCIENCE
     US18615817.617.6
     Intl615728(15.5)(10.2)(5.3)
     WW800886(9.6)(5.2)(4.4)
ONCOLOGY
US3,2612,83914.914.9
Intl4,731 4,266 10.920.8(9.9)
WW7,9927,10512.518.4(5.9)
     DARZALEX
     US1,974 1,461 35.135.1
     Intl1,868 1,337 39.752.2(12.5)
     WW3,842 2,798 37.343.3(6.0)
     ERLEADA
     US439 364 20.420.4
     Intl412 199  *  *  *
     WW850 563